KOZARICH JOHN W 4
4 · LIGAND PHARMACEUTICALS INC · Filed Mar 4, 2026
Insider Transaction Report
Form 4
KOZARICH JOHN W
Director
Transactions
- Sale
Common Stock
[F1][F2]2026-03-02$197.14/sh−47$9,266→ 43,140 total - Sale
Common Stock
[F1][F3]2026-03-02$199.69/sh−204$40,737→ 42,936 total - Sale
Common Stock
[F1][F4]2026-03-02$200.40/sh−41$8,217→ 42,895 total - Sale
Common Stock
[F1][F5]2026-03-02$201.65/sh−83$16,737→ 42,812 total - Sale
Common Stock
[F1][F6]2026-03-02$202.54/sh−50$10,127→ 42,762 total - Sale
Common Stock
[F1]2026-03-02$203.57/sh−42$8,550→ 42,720 total
Footnotes (6)
- [F1]The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $197.0650 to $197.2000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.4100 to $200.0550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $200.1050 to $200.8400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $201.2150 to $202.0500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $202.1500 to $202.8700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
By: s/ Andrew Reardon, Attorney-in-Fact For: John W. Kozarich|2026-03-04